Lipid Emulsion

Phase 2Small molecule

UUniversity of Rochester

Lipid Emulsion is one of 34 small molecule programs targeting Poisoning. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PoisoningActive, not recruiting

AbscessNot yet recruiting

PoisoningPreclinical

Active, not recruiting

AbscessPhase 2

Not yet recruiting

Competition

Competitive Landscape

35 competitors in Abscess

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

2 2

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

3 3

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

2 4

Duragesic

CCephalon

Approved

1 5

Flagyl

DDePuy Orthopaedics

Approved

1 6

Bactroban

PPadagis LLC

Approved

1 7

Zyvox

Pfizer

Phase 3

3 8

Lamprene

Novartis

Phase 3

2 9

Avelox

Bayer

Phase 3

1 10

Biaxin

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Abscess

NCT06052956

Q2 2032

Phase 2Not yet recruiting

Abscess

NCT07179003

Clinical

Trials by Indication[1]

Lipid Emulsion3 trials

Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.

Completed·MMikkel Bring Christensen·Phase 4·NCT02924454·10 enrolled

Lipid Emulsions and Liver Function - Results After 5 Years.

Completed·SStanley Dudrick's Memorial Hospital·Phase 4·NCT04347902·65 enrolled

Effects of Lipid Emulsions on Coagulation

Completed·MMimi Tang, PhD··NCT07470385·6,259 enrolled

Abscess2 trials

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Not yet recruiting·UUniversity of Rochester·Phase 2·NCT06052956·120 enrolled

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

Not yet recruiting·UUniversity of Rochester·Phase 2·NCT07179003·50 enrolled

Toxicity1 trial

Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity

Unknown status·AAya Sabry Mohamed Mohamed·Phase 4·NCT05006638·62 enrolled

Poisoning1 trial

Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning

Unknown status·—·N/A·NCT04807634·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Lipid Emulsion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipid Emulsion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipid Emulsion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Rochester company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Rochester

Lipid Emulsion

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Q2 2032

Trials by Indication[1]

Lipid Emulsion3 trials

Abscess2 trials

Toxicity1 trial

Poisoning1 trial

References

Drug Info

Quick Facts

Related News